When facing triple wild-type melanoma, the only therapy option available is immunotherapy, represented by anti-programmed cell death protein 1 (PD-1) and/or anti-cytotoxic T cell antigen 4 (CTLA-4) antibodies [7]. Here, CTLA4 is linked to melanoma.